Supplementary data



Supplementary Fig. S1: LA ameliorated DOX-induced alterations in lipid markers in serum. Rats (n = 6) were administered 15 mg/kg DOX with or without LA (500 mg/ kg for 14 days). One-way ANOVA was applied for statistical analysis, followed by post hoc Tukey's test using SPSS version 22.0.
***P <0.001 when compared with control.
###P < 0.001, ##P < 0.01 when compared with DOX.



Supplementary Fig. S2: LA ameliorated DOX-induced alterations in cardiac marker [creatine kinase-MB (CK-MB U/L)] in serum. Rats (n = 6) were administered 15 mg/kg DOX with or without LA (500 mg/ kg for 14 days). One-way ANOVA was applied for statistical analysis, followed by post hoc Tukey's test using SPSS version 22.0.
***P <0.001 when compared with control.
###P < 0.001, ##P < 0.01 when compared with DOX.



Supplementary Fig. S3: LA ameliorated DOX-induced alterations in cardiac marker [cardiac troponin I (cTnI ng/mL)] in serum. Rats (n = 6) were administered 15 mg/kg DOX with or without LA (500 mg/ kg for 14 days). One-way ANOVA was applied for statistical analysis, followed by post hoc Tukey's test using SPSS version 22.0.
***P <0.001 when compared with control.
###P < 0.001 when compared with DOX.



Supplementary Fig. S4: LA ameliorated DOX-induced alterations in cardiac marker [lactate dehydrogenase (LDH U/L)] in serum. Rats (n = 6) were administered 15 mg/kg DOX with or without LA (500 mg/ kg for 14 days). One-way ANOVA was applied for statistical analysis, followed by post hoc Tukey's test using SPSS version 22.0.
***P <0.001 when compared with control.
###P < 0.001 when compared with DOX.